Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma

Jaime‐Pérez, José Carlos; Gamboa-Alonso, Carmen Magdalena; Larracoechea, Alberto Vázquez-Mellado de; Rodríguez-Martínez, Marisol; Gutiérrez-Aguirre, César Homero; Marfil-Rivera, Luis Javier; Gómez‐Almaguer, David

doi:10.1016/j.arcmed.2015.07.004

Cited by 16 publications

(14 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The highest incidence rates among males were observed in Uruguay, Colombia, Peru, and Ecuador (i.e., 10.2-10.9%) and among females in Ecuador (i.e., 9.2%) and Peru (i.e., 8.8%), and these values were up to 40% lower than those observed in other countries (England, France, and Nor-DOI: 10.1159/000491989 way) and in North American countries for 2003-2007 [60]. A predominance of more aggressive subtypes of NHL has been described in Mexico and other developing countries [61,62]. Changes in exposure to risk factors, including infectious agents and immunosuppressive drugs, may be related to differences in demographic and geographic distribution patterns.…”

Section: Non-hodgkin's Lymphoma and Hodgkin's Lymphomamentioning

confidence: 97%

Geographic Hematology: Some Observations in Mexico

et al. 2018

View full text Add to dashboard Cite

In 1963 Jean Bernard introduced the concept of “geographic hematology” and distinguished 2 branches, i.e., “ethnic hematology,” which deals with differences between populations, and “environmental hematology,” which considers factors such as food habits, infections, and others. Both of these branches have implications in the distribution of hematological diseases worldwide. In comparison with Caucasian populations, in Mexico a significantly higher prevalence of acute lymphoblastic, acute promyelocytic, and acute megakaryoblastic leukemias has been described. The rate of chronic myeloid leukemia seems to be as high as that reported in Caucasian populations, while other myeloproliferative neoplasias are significantly less frequent in Mexico. Significantly lower prevalences of hairy cell leukemia, chronic lymphocytic leukemia, multiple myeloma, and Waldenström’s macroglobulinemia have been reported from Mexico. Regrettably, the influence of drug companies interested in selling their new and expensive drugs has resulted in both overdiagnosis of some diseases and overidentification of the refractory forms of some of these conditions to justify the use of unnecessary drugs.

show abstract

Section: Non-hodgkin's Lymphoma and Hodgkin's Lymphomamentioning

confidence: 97%

Geographic Hematology: Some Observations in Mexico

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Its incidence increases with age with a median at diagnosis of 66 years and a median age of death of 76 years in US statistics . In Latin America (LA), NHL presents at a mean of 57 years, 10 years earlier than in high‐income countries . Diffuse large B‐cell (DLBCL) is the more frequent subtype representing up to 60% in individuals more than 60 years of age .…”

Section: Clinical and Demographic Characteristics Of 83 Elderly Patiementioning

confidence: 99%

“…1 In Latin America (LA), NHL presents at a mean of 57 years, 10 years earlier than in high-income countries. 2 Diffuse large B-cell (DLBCL) is the more frequent subtype representing up to 60% in individuals more than 60 years of age. 3 There is limited information on treatment and outcomes in this age group from the LA region.…”

Section: Introductionmentioning

confidence: 99%

Treatment of diffuse large B‐cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10‐year results at a Latin American center

Jaime‐Pérez

Padilla-Medina

Salazar‐Cavazos

et al. 2019

Hematological Oncology

View full text Add to dashboard Cite

“…In Mexico, hematologic malignancies accounted for 7% of all cancers and 9.8% of cancer deaths in adults ≥20 years of age in 2018 [1]. Compared to high-income countries, patients with hematologic malignancies in Mexico are characterized by being at high risk and advanced stages at diagnosis and by having a lower cure rate [2][3][4][5][6]. Hematologic malignancies negatively affect the quality of life and wellbeing of patients.…”

Section: Introductionmentioning

confidence: 99%

Experiences with health care and health-related quality of life of patients with hematologic malignancies in Mexico

Doubova

Terreros-Muñoz

Delgado-López

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: In Mexico, patients with hematologic malignancies (HMs) are characterized by being at high risk and advanced stages at diagnosis and by having a low cure rate; yet information on their experiences with health care and health-related quality of life (HRQL) is scarce. We aimed to evaluate experiences with health care and HRQL of patients with HMs and the association between these patient-reported measures. Methods: We conducted a cross-sectional survey in two public oncology hospitals in Mexico City. The study included outpatient cancer patients aged ≥18 years with a diagnosis of leukemia, lymphoma, or multiple myeloma. We used a patient-centered quality of cancer care questionnaire to assess patient experiences with receiving 1) timely care; 2) clear information; 3) information for treatment decision-making; 4) care to address biopsychosocial needs; and 5) respectful and coordinated care. We applied the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) to measure HRQL. We performed a multiple linear regression to evaluate the association between patient-reported experiences (independent variables) and the QLQ-C30 summary score (dependent variable). Results: Of the 515 participating HM patients, 46.6% had lymphoma, 34% leukemia, and 19.4% multiple myeloma; 70.9% were at advanced stages or at high risk. Additionally, 15.1% had anxiety and 12.8% had depression. Over one third (35.9%) reported receiving clear information, 28.5% timely care, 20.6% information for treatment decision-making, 23.7% care that addressed their biopsychosocial needs, and 31% respectful and coordinated care. The mean QLQ-C30 summary score was 71.9 points. Timely care, clear information, and care that addresses biopsychosocial needs were associated with higher HRQL. Conclusions: Health care services for HM patients at public oncology hospitals in Mexico need improvement. Notably, providing timely care, clear information, and care that addresses patients’ biopsychosocial needs can increase the likelihood of better HRQL. Health care providers should measure and improve the experiences of HM patients with health care.

show abstract

Non-Hodgkin Lymphomas: Impact of Rituximab on Overall Survival of Patients with Diffuse Large B-Cell and Follicular Lymphoma

Cited by 16 publications

References 29 publications

Geographic Hematology: Some Observations in Mexico

Geographic Hematology: Some Observations in Mexico

Treatment of diffuse large B‐cell lymphoma with and without anthracyclines and rituximab in patients older than 60 years: 10‐year results at a Latin American center

Experiences with health care and health-related quality of life of patients with hematologic malignancies in Mexico

Contact Info

Product

Resources

About